ABVC ABVC BioPharma, Inc: Long-Term Debt to Capital Coefficient

ABVC BioPharma develops plant-based medicines for ADHD, depression, and cancer, mitigating risks through strategic partnerships. The long-term financial debt sustainability indicator demonstrates a liability structure where the value of 0.14 reflects this status. Business success depends exclusively on the outcomes of clinical molecule trials. Team flexibility is ensured by fully outsourcing production and research to external contractors.

To select high-quality assets, an investor must exclude issuers with excessive debt loads. This metric correlates liabilities with a term of more than one year to equity, identifying risks of shareholder dilution. For ABVC BioPharma (ABVC), the humanitarian status of its developments reduces reliance on external loans. The stability of this structure confirms financial resilience under a dual listing. Analyzing changes in the long-term debt-to-equity ratio allows for an assessment of the safety of the growth strategy.